Paediatric and adolescent COVID-19 vaccines update
The EMA is evaluating whether to lower the age at which Comirnaty can be administered and Novavax has begun testing its COVID-19 vaccine in paediatric patients.
List view / Grid view
News
Remestemcel-L reduces ARDS mortality in those under 65 years old
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.
![A cryomicroneedle patch ready for deployment [Credit: Chang et al. /DOI number: 10.1038/s41551-021-00720-1].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cryomicroneedle-patch-300x278.jpg)
![A cryomicroneedle patch ready for deployment [Credit: Chang et al. /DOI number: 10.1038/s41551-021-00720-1].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cryomicroneedle-patch-e1620132484839.jpg)
Novel cryomicroneedle patch successfully delivers therapeutic cells in mice
Researchers have developed a new generation of microneedle technology which allows for the intradermal delivery of living cells in a minimally invasive manner.
Cell-based seasonal influenza vaccine safe and effective in children
Phase III data shows Seqirus’ cell-based quadrivalent seasonal influenza vaccine was as effective and safe as an equivalent FDA-approved egg-based vaccine in paediatric patients.
Moderna invests to increase global supply of its COVID-19 vaccine
According to Moderna, its new investments could increase global supply of its COVID-19 vaccine to one billion doses in 2021 and three billion in 2022.
Amcor begins consumer trials of recyclable pharmaceutical blister packaging
Amcor’s new recyclable packaging solution, AmSky™, is expected to be available in the healthcare market by the second half of 2022.
$150 million made available for COVID-19 vaccine adverse event compensation scheme
The COVAX No-fault Compensation Program will offer individuals in 92 lower-income countries and economies compensation for serious adverse events associated with COVID-19 vaccines distributed through COVAX.
EMA to assess if Olumiant should be authorised for hospitalised COVID-19 patients
The EMA will conduct an accelerated assessment and issue its decision on whether Olumiant (baricitinib) can be used in hospitalised COVID-19 patients by July.
COVID-19 manufacturing requirements are lucrative for CMOs, says GlobalData
A new report shows half the drugs and all the vaccines approved for emergency use in 2020 had an associated contract manufacturing agreement.
Highest British business award goes to cannabis drug developer, GW Pharmaceuticals
The Queen’s Award for Enterprise in Innovation was awarded to GW for leadership in cannabinoid science and development of prescription cannabis-based medicines.
100 percent recovery rate for COVID-19 patients treated with Zofin™
The first ten patients in a Phase I trial of Zofin™ have recovered and been discharged, the trial will now expand with an additional 65 participants.
Acceleron receives FDA Notice of Noncompliance
The Notice of Noncompliance gives Acceleron 30 days to submit the required clinical trial results information to ClinicalTrials.Gov or face financial penalties.
Ampion™ reduces COVID-19 respiratory distress mortality
The final results from the Phase I trial show treatment with Ampion™ reduced all-cause mortality by almost 80 percent in COVID-19 patients with respiratory distress.
ISPE announces its manufacturing Facility of the Year Awards winners
The awardees, including Takeda, Janssen and Gilead, are recognised for their state-of-the-art facility design, construction and operation projects.
First patient dosed with dalbavancin in S. aureus bacteremia trial
The trial will assess the efficacy of a two week regimen of the FDA-approved antibiotic dalbavancin in treating 100 patients with Staphylococcus aureus bacteremia.
